Amundi
RVNC

Amundi’s Revance Therapeutics, Inc. RVNC Stock Holding History

Amundi’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-228
Closed -$773 – 2269
2024
Q4 		$773 Buy
+228
New +$993 ﹤0.01% 2056

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Amundi's RVNC Position: Q1 2025 in Review

Amundi sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 228 shares — an estimated $773 sold.

Amundi first reported a position in RVNC in Q4 2024 and held it in 1 quarter. The position peaked at $773 in Q4 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Amundi reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Amundi sold 228 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $773.
  • Amundi first reported a position in Revance Therapeutics, Inc. in Q4 2024 and held it in 1 quarter.
  • Amundi's Revance Therapeutics, Inc. position peaked at $773 in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Amundi's 13F filing for Q1 2025, filed 15 May 2025.